Definition
Cryofibrinogenemia is a rare hematologic disorder characterized by the presence of abnormal plasma proteins—principally fibrinogen, fibrin, and sometimes immunoglobulins—that precipitate at temperatures below normal body temperature (typically ≤ 37 °C) and dissolve upon re‑warming. The precipitates, termed cryofibrinogen, can occlude small vessels and lead to a variety of cutaneous, vascular, and systemic manifestations.
Pathophysiology
The condition involves the reversible formation of insoluble complexes composed of fibrinogen, fibrin, possibly factor VIII, and plasma lipids when the blood is cooled. These complexes may aggregate with platelets and leukocytes, forming intravascular or extravascular clots. The exact molecular trigger for precipitation is not fully elucidated, but alterations in fibrinogen structure, the presence of circulating cryoglobulins, or abnormal lipid profiles can contribute. Unlike cryoglobulinemia, the precipitating material in cryofibrinogenemia remains in the plasma phase and does not precipitate in serum after clotting.
Classification
Cryofibrinogenemia is divided into:
- Primary (essential) cryofibrinogenemia – occurs without an identifiable underlying disease.
- Secondary cryofibrinogenemia – associated with other medical conditions, including infections (e.g., bacterial endocarditis, tuberculosis), autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis), malignancies (particularly solid tumors and lymphomas), and hereditary lipid disorders.
Epidemiology
The disorder is uncommon, with reported prevalence ranging from 0.5 to 1.0 % in selected laboratory screening series. It exhibits a slight male predominance and is most frequently diagnosed in adults between the ages of 30 and 60 years. Precise incidence and prevalence data are limited due to under‑recognition and variability in diagnostic testing.
Clinical Manifestations
| System | Typical Findings |
|---|---|
| Cutaneous | Painful erythematous or purplish plaques, livedo reticularis, ulcerations, gangrene of extremities, and cold‑induced acrocyanosis. |
| Vascular | Raynaud‑like phenomena, peripheral arterial or venous thrombosis, digital ischemia. |
| Neurologic | Peripheral neuropathy secondary to ischemia; rare central nervous system involvement. |
| Systemic | Fever, arthralgia, fatigue; organ‑specific ischemic injury (e.g., renal, gastrointestinal) is uncommon but reported. |
Symptoms frequently exacerbate with exposure to cold environments and improve with warming.
Diagnosis
-
Laboratory Testing
- Collection of citrated plasma (not serum) maintained at 37 °C.
- Cooling the plasma to 4 °C for 1–2 hours; observation of precipitation.
- Re‑warming the sample to confirm dissolution.
- Quantification of cryofibrinogen concentration (typically expressed in mg/dL).
-
Exclusion of Cryoglobulinemia
- Serum (post‑clot) remains clear after cooling, distinguishing cryofibrinogenemia from cryoglobulinemia.
-
Ancillary Studies
- Complete blood count, erythrocyte sedimentation rate, C‑reactive protein, complement levels, and autoantibody panels to assess for secondary causes.
- Imaging (doppler ultrasound, angiography) if vascular occlusion is suspected.
Management
- Avoidance of Cold – Protective clothing and environmental temperature control are fundamental preventive measures.
- Pharmacologic Therapy
- Anticoagulants (e.g., low‑molecular‑weight heparin, warfarin) to reduce thrombotic risk.
- Corticosteroids may be employed, especially in secondary forms linked to autoimmune disease.
- Immunosuppressive agents (e.g., cyclophosphamide, azathioprine) for refractory cases or when associated with systemic vasculitis.
- Plasmapheresis has been used acutely to remove circulating cryofibrinogen in severe presentations.
- Treatment of Underlying Condition – In secondary cryofibrinogenemia, addressing the primary disease (e.g., antibiotics for infection, chemotherapy for malignancy) often leads to resolution of laboratory abnormalities and clinical signs.
Prognosis
The clinical course varies. Primary cryofibrinogenemia may persist with intermittent flares, whereas secondary forms often improve with successful treatment of the associated disorder. Persistent severe vascular occlusion can lead to tissue loss and functional impairment. Early recognition and avoidance of cold exposure are associated with better outcomes.
History
The phenomenon of cold‑induced fibrinogen precipitation was first described in the early 20th century, with the term “cryofibrinogenemia” introduced in the 1960s following laboratory characterization of the precipitate. Subsequent studies differentiated it from cryoglobulinemia and identified its association with diverse systemic illnesses.
Research Directions
Current investigations focus on elucidating the molecular alterations in fibrinogen that predispose to cold precipitation, identifying genetic susceptibilities, and developing targeted therapies that prevent cryofibrinogen formation without systemic anticoagulation.
This entry reflects currently available encyclopedic information on cryofibrinogenemia as of the 2026 knowledge cutoff.